History of regional chemotherapy for cancer of the extremities

International Journal of Hyperthermia

Volumn 24, Issue 3, 2008, Pages 185-192

  Ariyan, Charlotte Eielson ^a   Brady, Mary Sue ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical trials; Isolated limb perfusion

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CARBOPLATIN; CISPLATIN; DACARBAZINE; DACTINOMYCIN; DOPAMINE; GAMMA INTERFERON; HEMOGLOBIN; MELPHALAN; THIOTEPA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; HEMOGLOBINURIA; HUMAN; HYPERTHERMIC THERAPY; KIDNEY DISEASE; LIMB AMPUTATION; LIMB DISEASE; LIMB PERFUSION; LYMPH NODE DISSECTION; MEDICAL LITERATURE; MELANOMA; MONOTHERAPY; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE EDEMA; POSTOPERATIVE HEMORRHAGE; RECURRENT CANCER; REVIEW; SARCOMA; SOFT TISSUE CANCER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT;

CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPERTHERMIA, INDUCED; MELANOMA; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS;

EID: 42049120561     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730701785102     Document Type: Review

References (50)

1. Balch, CM, Houghton, AN, Sober, AJ and Soong, SJ (2003) Cutaneous Melanoma, Quality Medical Publishing, Inc., St Louis, MO
2. Koops, HS, Vaglini, M. and Suciu, S. (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol, 16:9, pp. 2906-2912.
3. Cascinelli, NN, Bufalino, RR and Marolda, RR (1986) Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol, 12:2, pp. 175-180.
4. Sutherland, CM, Mather, FJ and Krementz, ET (1987) Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg, Gynecol Obstet, 164:2, pp. 111-118.
5. Jacques, DP, Coit, DG and Brennan, MF (1989) Major amputation for advanced malignant melanoma. Surg Gynecol Obstet, 169:1, pp. 1-6.
6. Creech, OO, Krementz, EET, Ryan, RRF and Winblad, JJN (1958) Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Annals Surg, 148:4, pp. 616-632.
7. Luck, J. (1961) Further observations on the efficacy of phenylalanine mustards against mouse melanoma. Cancer Res, 21, pp. 262-264.
8. Gram, CM HF and Baker, BR (1959) Potential anticancer agents. Alkylating agents to phenylalanine mustard. J Chem Soc, 81, pp. 3103-3108.
9. Krementz, ET, Carter, RD, Sutherland, CM, Muchmore, JH, Ryan, RF and Creech, O. (1994) Regional chemotherapy for melanoma. A 35-year experience. Annals Surg, 220:4, pp. 520-534.
10. Creech, OO, Krementz, ET, Ryan, RF, Reemtsma, KK and Winblad, JN (1959) Experiences with isolation-perfusion technics in the treatment of cancer. Annals Surg, 149:5, pp. 627-640.
11. Cavaliere, RR, Ciocatto, EC and Giovanella, BC (1967) Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer, 20:9, pp. 1351-1381.
12. Stehlin, JS (1969) Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg, Gynecol Obstet, 129:2, pp. 305-308.
13. McBride, CM, Sugarbaker, EV and Hickey, RC (1975) Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Annals Surg, 182:3, pp. 316-324.
14. MAC, DG Brady (2000) Current Clinical Oncology: Regional Chemotherapy, Humana Press Inc., Totowa, NJ
15. Wieberdink, J., Benckhuysen, C., Braat, RR, van Slooten, EA and Olthuis, GA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer, 18:10, pp. 905-910.
16. Sanki, A., Kam, PC and Thompson, JF (2007) Long-term results of hyperthermic, isolated limb perfusion for melanoma: A reflection of tumor biology. Annals Surg, 245:4, pp. 591-596.
17. Cornett, WR, McCall, LM and Petersen, RP (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol, 24:25, pp. 4196-4201.
18. HR, KH Franklin, Oldhoff, J., Czarnetzki, BM, Macher, E., Kroon, BB, Welvaart, K., van der Velden, JW, van Dijk, E., van der Esch, EP, Oosterhuis, JW, Huisman, SJ, Hart, AA and Rumke, P. (1988) To perfuse or not perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5mm or greater. J Clin Oncol, 6:4, pp. 701-708.
19. Ghussen, F., Nagel, K., Groth, W., Müller, JM and Stützer, H. (1984) A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Annals Surg, 200:6, pp. 764-768.
20. Ghussen, F., Krüger, I., Smalley, R. and Groth, W. (1989) Hyperthermic perfusion with chemotherapy for melanoma of the extremities. World J Surg, 13:5, pp. 598-602.
21. WS, PR Fletcher and Small, K. (1994) Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma. Melanoma Res, 4, p. 19.
22. DG, BD Coit and Menendex-Botet, C. (1991) Phase I trial of hyperthermic isolation limb perfusion (HILP) using cisplatin (CDDP) for metastatic melanoma. Proc Am Soc Clin Oncol, 10
23. Thompson, JF and Gianoutsos, MP (1992) Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg, 16:2, pp. 227-233.
24. Vaglini, M., Belli, F., Marolda, R., Prada, A., Santinami, M. and Cascinelli, N. (1987) Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities. Eur J Surg Oncol, 13:2, pp. 127-129.
25. Ariyan, S. (2003) Regional isolated perfusion of extremities for melanoma: Now a 26-year experience with drugs other than L-phenylalanine mustard. Plastic Reconst Surg, 111:3, pp. 1257-1261.
26. Carswell, EA, Old, LJ, Kassel, RL, Green, SS, Fiore, NN and Williamson, BB (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Nat Acad Sci USA, 72:9, pp. 3666-3670.
27. Green, S., Dobrjansky, A. and Carswell, EA (1976) Partial purification of a serum factor that causes necrosis of tumors. Proc Nat Acad Sci USA, 73:2, pp. 381-385.
28. Williamson, BD, Carswell, EA, Rubin, Prendergast, JS and Old, LJ (1983) Human tumor necrosis factor produced by human B-cell lines: Synergistic cytotoxic interaction with human interferon. Proc Nat Acad Sci USA, 80:17, pp. 5397-5401.
29. van Horssen, R., Hagen, TL Ten and Eggermont, AM (2006) TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncol, 11:4, pp. 397-408.
30. Posner, MC, Lienard, D., Lejeune, FJ, Rosenfelder, D. and Kirkwood, J. (1995) Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Amer, 1:4, pp. 274-280.
31. Brouckaert, PG, Leroux-Roels, GG, Guisez, Y., Tavernier, J. and Fiers, W. (1986) In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer, 38:5, pp. 763-769.
32. Lienard, D., Ewalenko, P., Delmotte, J., Renard, N. and Lejeune, F. (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol, 10:1, pp. 52-60.
33. Lienard, D., Eggermont, AM, Koops, HS, Kroon, B., Towse, G., Hiemstra, S., Schmitz, P., Clarke, J., Steinmann, G., Rosenkaimer, F. and Lejeune, FJ (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res, 9:5, pp. 491-502.
34. Garrido-Laguna, I., Ponz, M. and Espinós, J. (2007) Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?. J Clin Oncol, 25:9, pp. 1149-1151.
35. JF, WR Thompson, Saw, RP and Kam, PC (1993) Isolated limb infusion (ILI) with melphalan for recurrent limb melanoma. Reg Cancer Treat, 6, pp. 51-52.
36. Brady, MS, Brown, K., Patel, A., Fisher, C. and Marx, W. (2006) A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Annals Surg Oncol, 13:8, pp. 1123-1129.
37. Siemann, DW, Chapman, M. and Beikirch, A. (1991) Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol, Biol, Phys, 20:2, pp. 287-289.
38. Thompson, JF, Kam, PC, Waugh, RC and Harman, CR (1998) Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Seminars Surg Oncol, 14:3, pp. 238-247.
39. Filippo, FF Di, Calabrò, AA and Giannarelli, DD (1989) Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer, 63:12, pp. 2551-2561.
40. Storm, FK and Morton, DL (1985) Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg, 150:1, pp. 32-35.
41. Minor, DR, Allen, RE, Alberts, D., Peng, YM, Tardelli, G. and Hutchinson, J. (1985) A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer, 55:11, pp. 2638-2644.
42. Kroon, BB, Van Geel, AN, Benckhuijsen, C. and Wieberdink, J. (1987) Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res, 7:3, pp. 441-442.
43. Kroon, BB, Klaase, JM, van Geel, BN, Eggermont, AM, Franklin, HR and van Dongen, JA (1993) Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer, 29:3, pp. 325-328.
44. Klaase, JJM, Kroon, BBB and van Geel, AAN (1994) Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surgeons., 178:6, pp. 564-572.
45. Edwards, MJ, Soong, SJ, Boddie, AW, Balch, CM and McBride, CM (1990) Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone. Archives Surg, 125:3, pp. 317-321.
46. Fraker, DL, Alexander, HR, Andrich, MM and Rosenberg, SA (1996) Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study. J Clin Oncol, 14:2, pp. 479-489.
47. Eggermont, AM, Koops, HH Schraffordt and Klausner, JM (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Annals Surg, 224:6, pp. 756-764.
48. Grünhagen, DJ, Brunstein, F., Graveland, WJ, van Geel, AN, de Wilt, JH and Eggermont, AM (2004) One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Annals Surg, 240:6, pp. 939-947.
49. Noorda, EM, Vrouenraets, BC, Nieweg, OE, van Geel, BN, Eggermont, AM and Kroon, BB (2004) Isolated limb perfusion for unresectable melanoma of the extremities. Archives Surg, 139:11, pp. 1237-1242.
50. Rossi, CR, Foletto, M., Mocellin, SS, Pilati, P. and Lise, M. (2004) Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Annals Surg Oncol, 11:2, pp. 173-177.